Combating arthritis, multiple sclerosis, gout and other auto-immune diseases could be possible with two compounds - one naturally derived from fasting and another from intensive exercise, said researchers on Monday.
The compounds throw a wrench into a molecular mechanism that causes inflammation, a driver of these diseases, the teams reported in Nature Medicine.
Quiz on Arthritis
Do you know that there are more than 100 types of arthritis? If you think that only old people suffer from arthritis, take this intriguing quiz to get your facts on arthritis.
Advertisement
Called beta-hydroxybutyrate (BHB) and MCC950, the compounds may open up an intriguing avenue in drug research, they said.
The hope is that the mechanism they target, NLRP3, proves to be common to all auto-immune diseases, regardless of which part of the body is affected.
![Antihypertensive Drugs and Risk of Incident Gout Among Patients With Hypertension]( "Antihypertensive Drugs and Risk of Incident Gout Among Patients With Hypertension")
Hypertension is one of the most common comorbidities of gout. 74% of patients with gout have hypertension.
"Drugs like aspirin or steroids can work in several diseases, but can have side effects or be ineffective," said Luke O'Neill, a biochemistry professor at Trinity College Dublin, whose team worked with Australian scientists on MCC950.
"What we have found is a potentially transformative medicine, which targets what appears to be the common disease-causing process in a myriad of inflammatory diseases."
BHB was found separately by researchers at the Yale School of Medicine.
It is a metabolite -- a product of metabolism that results from fasting, high-energy exercise or the low-carb "ketogenic" diet.
So far, the compounds have lowered inflammation in mice with multiple sclerosis, a condition called Muckle-Wells syndrome and familial cold auto-inflammatory disease -- fever and joint pain that occur after exposure to cold temperatures.
Years of trials will be needed to see if they work on humans and are safe.
Source: AFP
Antihypertensive Drugs and Risk of Incident Gout Among Patients With Hypertension
Hypertension is one of the most common comorbidities of gout. 74% of patients with gout have hypertension.
Advertisement
"Drugs like aspirin or steroids can work in several diseases, but can have side effects or be ineffective," said Luke O'Neill, a biochemistry professor at Trinity College Dublin, whose team worked with Australian scientists on MCC950.
"What we have found is a potentially transformative medicine, which targets what appears to be the common disease-causing process in a myriad of inflammatory diseases."
BHB was found separately by researchers at the Yale School of Medicine.
It is a metabolite -- a product of metabolism that results from fasting, high-energy exercise or the low-carb "ketogenic" diet.
So far, the compounds have lowered inflammation in mice with multiple sclerosis, a condition called Muckle-Wells syndrome and familial cold auto-inflammatory disease -- fever and joint pain that occur after exposure to cold temperatures.
Years of trials will be needed to see if they work on humans and are safe.
Source: AFP
Multiple Sclerosis
Multiple sclerosis can be a severely disabling autoimmune disease that affects the myelin or insulating layer of the nerve fibers and typically has remissions and relapses
Advertisement
 Foods that Can Save Your HeartDo you enjoy a glass of wine with your meal? If so it's good news for your heart! | Advertisement
|
Advertisement
Recommended Reading
Latest Drug News
India's First Urinary Incontinence Drug Fesobig may offer Affordable treatment for Overactive Bladder (OAB), a widely prevalent problem among Indian men and women.
Oral anticoagulant drugs, particularly Rivaroxaban presented superior efficacy and safety than warfarin in atrial fibrillation patients with chronic kidney disease.
Patients with hepatitis D virus-related chronic advanced liver disease are treated with an antiviral therapy.
Among people with COVID-19, Paxlovid drug was found to reduce hospitalization and death risk by 90%, revealed study.
Lilly will likely maintain or increase its market share in the insulin space as the average out-of-pocket cost for its insulin products is already below the $35 price cap.